This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Roche Molecular Systems, Inc., Aarhus Universitet. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 647 
1 out of 71 
Years Active: 2018
Title: Innovations by Wei Wen in Cancer Monitoring
Introduction
Wei Wen is an accomplished inventor based in Santa Clara, CA, known for his significant contributions to cancer monitoring technologies. With a total of two patents, his work focuses on improving methods for assessing the status of solid-tumor cancers through innovative blood testing techniques.
Latest Patents
Wei Wen's latest patents include groundbreaking methods for EGFR blood monitoring and mutation testing. The EGFR blood monitoring patent involves improved methods of assessing the status of solid-tumor cancer in a subject by detecting tumor-associated mutations in the subject's blood. Similarly, his mutation testing patent enhances the assessment of solid tumor cancer status through the detection of these critical mutations.
Career Highlights
Throughout his career, Wei Wen has worked with notable organizations, including Roche Molecular Systems, Inc. and Aarhus University. His experience in these institutions has allowed him to develop and refine his innovative approaches to cancer diagnostics.
Collaborations
Wei Wen has collaborated with esteemed colleagues such as Peter Meldgaard and Boe Sorensen, contributing to the advancement of cancer monitoring technologies.
Conclusion
Wei Wen's innovative work in cancer monitoring through blood testing has the potential to significantly impact the field of oncology. His patents reflect a commitment to improving patient outcomes and advancing medical technology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile